Coronary Artery Disease, Sleep Apnea Syndrome
Conditions
Keywords
Apnea syndrome, Coronary artery disease, Oxidative stress, Continuous positive airway pressure, Endothelial dysfunction
Brief summary
Published data indicate that obstructive sleep apnea syndrome (OSAS) worse the prognosis of coronary artery disease (CAD) and that oxidative stress can link this 2 diseases. Investigators hypothesise that oxidative stress decrease after 3 months of continuous positive airway pressure (CPAP) in this specific population. The results may have major implication in the comprehension of physiopathologic processes linking OSAS and CAD and in the treatment of OSAS in this specific population.
Detailed description
Obstructive sleep apnea syndrome (OSAS) is a common disorder characterized by recurrent upper airway collapse during sleep and has been associated with worsened prognosis in patients with coronary artery disease (CAD). Moderate OSAS can be defined by an apnea hypopnea index (AHI) between 15 and 30 events/hour. Pathophysiologic processes are complex and it seems that oxidative stress play and important role. Studies showed that continuous positive airway pressure (CPAP) influence oxidative stress but the results are conflicting. Moreover there are uncertainties whether diagnosing and treating OSAS can influence the pathophysiological and clinical outcomes in patients with CAD. Therefore, we aim to test the effects of 3 months of CPAP on systemic redox balance evaluated by plasma GSH/GSSG ratio. Patients with moderate OSAS will be randomized for the intervention. Patients with AHI \<15/h or \>30/h will be included in an ancillary study (blood and urinary test, MIBG scintigraphy) to characterize the biological profile of coronary patients based on their AHI. For a alpha threshold of 5% and a study power of 80%, the study should include 16 patients in each group. Taking in account a possible 20% of dropout the study will need to include 20 patients by randomized arm to demonstrate an effect.
Interventions
DEVICEContinuous positive airway pressure
Continuous positive airway pressure treatment during three months with adherence recording
Sham-continuous positive airway pressure during three months with adherence recording
Sponsors
University Hospital, Montpellier
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
30 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Apnea Hypopnea Index 15-30/h * Stable Coronary artery disease * Obligation of obtaining informed consent form
Exclusion criteria
* Heart failure with LVEF less than or equal to 45% * Other Chronic disease: renal failure, COPD Index - central apneas than or equal to 50% of the total IAH * treatment with CPAP or mandibular advancement device * IMC\> 40 kg / m² * Nutritional supplementation in the 4 weeks preceding the study (antioxidants, vitamins ...). * Treatment with allopurinol or N-acetylcysteine, in the 4 weeks preceding the study. * PaCO2\> 45 mmHg - Counter-indication to the use of PPC: bullous lung disease, pathological hypotension, bypass airway, pneumothorax, signs of sinus infections or inner ear * Exclusion period on subject compared to another protocol or for which the maximum annual amount of compensation of € 4,500 has been reached. * Participation of the subject to another study. * Not affiliated with a social security scheme subject or not the beneficiary of such a regime. * Pregnant or breastfeeding women, patient unable to give consent, protected adult, vulnerable * Subject deprived of liberty by judicial or administrative decision * HIV infection, hepatitis B or hepatitis C known
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage change of serum GSH/GSSG ratio | at the inclusion and the end (3 months) of the study | Blood test |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change, after 3 months, of the catalase (parameters of serum oxidative stress level) | at the inclusion and the end (3 months) of the study | — |
| Change, after 3 months, of the Vit C and E (parameters of serum oxidative stress level) | at the inclusion and the end (3 months) of the study | — |
| Change, after 3 months, of the isoprostanes (parameter of serum oxidative stress level) | at the inclusion and the end (3 months) of the study | — |
| Change, after 3 months, of the 8OHDG (other parameters of serum oxidative stress level) | at the inclusion and the end (3 months) of the study | by blood test |
| Change, after 3 months, of the GPX (parameter of serum oxidative stress level) | at the inclusion and the end (3 months) of the study | — |
| Change, after 3 months, of the inflammation parameters: IL6, IL8, TNF α (blood test) | at the inclusion and the end (3 months) of the study | — |
| Change, after 3 months, of the urinary catecholamines by urine test | at the inclusion and the end (3 months) of the study | — |
| Change, after 3 months, of the SOD (parameter of serum oxidative stress level) | at the inclusion and the end (3 months) of the study | — |
| Change, after 3 months, of the endothelial function (endoPat) | at the inclusion and the end (3 months) of the study | — |
| Change, after 3 months, of the blood pressure | at the inclusion and the end (3 months) of the study | 24h ambulatory blood pressure monitoring |
| Change, after 3 months, of the quality of life by the SF 36 questionnaire | at the inclusion and the end (3 months) of the study | — |
| Change, after 3 months, of the quality of sleep by PSQI questionnaire | at the inclusion and the end (3 months) of the study | — |
| Change, after 3 months, of the sleepiness by the Epworth scale | at the inclusion and the end (3 months) of the study | — |
| Change, after 3 months, of the physical activity by the Voorips questionnaire | at the inclusion and the end (3 months) of the study | — |
| Change, after 3 months, of the MIBG scintigraphy | at the inclusion and the end (3 months) of the study | — |
Countries
France
Outcome results
None listed